239 related articles for article (PubMed ID: 38618505)
21. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.
Fuller JR; Knockenhauer KE; Leksa NC; Peters RT; Batchelor JD
Blood; 2021 May; 137(21):2970-2980. PubMed ID: 33569592
[TBL] [Abstract][Full Text] [Related]
22. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
[TBL] [Abstract][Full Text] [Related]
23. Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease.
Biguzzi E; Siboni SM; le Cessie S; Baronciani L; Rosendaal FR; van Hylckama Vlieg A; Peyvandi F
J Thromb Haemost; 2021 Jan; 19(1):96-106. PubMed ID: 32998182
[TBL] [Abstract][Full Text] [Related]
24. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
25. Periprocedural management of type 2N von Willebrand disease with efanesoctocog alfa.
Ryu JH; Bauer KA; Schulman S
J Thromb Haemost; 2023 Dec; 21(12):3508-3510. PubMed ID: 37734716
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
27. Activated factor VIII-mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions.
Yaoi H; Shida Y; Kitazawa T; Shima M; Nogami K
Thromb Res; 2021 Feb; 198():7-16. PubMed ID: 33248318
[TBL] [Abstract][Full Text] [Related]
28. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
29. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
[TBL] [Abstract][Full Text] [Related]
30. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
31. Mice deficient in the anti-haemophilic coagulation factor VIII show increased von Willebrand factor plasma levels.
Kiouptsi K; Grill A; Mann A; Döhrmann M; Lillich M; Jäckel S; Malinarich F; Formes H; Manukyan D; Subramaniam S; Khandagale A; Karwot C; Thal SC; Bosmann M; Scharrer I; Jurk K; Reinhardt C
PLoS One; 2017; 12(8):e0183590. PubMed ID: 28837614
[TBL] [Abstract][Full Text] [Related]
32. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
33. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
34. Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient.
Kurian CJ; Drelich DA; Rizk S
J Thromb Haemost; 2020 Apr; 18(4):853-856. PubMed ID: 31997485
[TBL] [Abstract][Full Text] [Related]
35. Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels.
Sabater-Lleal M; Huffman JE; de Vries PS; Marten J; Mastrangelo MA; Song C; Pankratz N; Ward-Caviness CK; Yanek LR; Trompet S; Delgado GE; Guo X; Bartz TM; Martinez-Perez A; Germain M; de Haan HG; Ozel AB; Polasek O; Smith AV; Eicher JD; Reiner AP; Tang W; Davies NM; Stott DJ; Rotter JI; Tofler GH; Boerwinkle E; de Maat MPM; Kleber ME; Welsh P; Brody JA; Chen MH; Vaidya D; Soria JM; Suchon P; van Hylckama Vlieg A; Desch KC; Kolcic I; Joshi PK; Launer LJ; Harris TB; Campbell H; Rudan I; Becker DM; Li JZ; Rivadeneira F; Uitterlinden AG; Hofman A; Franco OH; Cushman M; Psaty BM; Morange PE; McKnight B; Chong MR; Fernandez-Cadenas I; Rosand J; Lindgren A; ; Gudnason V; Wilson JF; Hayward C; Ginsburg D; Fornage M; Rosendaal FR; Souto JC; Becker LC; Jenny NS; März W; Jukema JW; Dehghan A; Trégouët DA; Morrison AC; Johnson AD; O'Donnell CJ; Strachan DP; Lowenstein CJ; Smith NL
Circulation; 2019 Jan; 139(5):620-635. PubMed ID: 30586737
[TBL] [Abstract][Full Text] [Related]
36. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.
Jacquemin M; Lavend'homme R; Benhida A; Vanzieleghem B; d'Oiron R; Lavergne JM; Brackmann HH; Schwaab R; VandenDriessche T; Chuah MK; Hoylaerts M; Gilles JG; Peerlinck K; Vermylen J; Saint-Remy JM
Blood; 2000 Aug; 96(3):958-65. PubMed ID: 10910910
[TBL] [Abstract][Full Text] [Related]
37. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
38. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Kroner PA; Foster PA; Fahs SA; Montgomery RR
Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
[TBL] [Abstract][Full Text] [Related]
40. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Jacquemin M
Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
